Merit Medical Systems Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C

Reuters

05-21

<a href="https://laohu8.com/S/MMSI">Merit Medical Systems</a> Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C

Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000035), on May 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537236376"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537236376\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537236376?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537236376","market":"nz","top_or_hot":-1,"title":"Merit Medical Systems Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a> Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000035), on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merit Medical Systems Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerit Medical Systems Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-21 04:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a> Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000035), on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLFS","symbol_name":"BioLife Solutions Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL9slT3Z:1","article_id":"2537236376","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537236376","pubTimestamp":1747772242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLFS":"BioLife Solutions Inc.","BK4121":"生命科学工具和服务","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","MMSI":"Merit Medical Systems","BK4198":"医疗保健用品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"梅里特医疗系统公司。收购Biolife Delaware，L.L.C.后更新2025年财务指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":0.9,"MMSI":0.9},"content_text":"Merit Medical Systems Inc. Updates 2025 Financial Guidance Following Acquisition of Biolife Delaware, L.L.C\n    \n\n        Merit Medical Systems Inc., a leader in healthcare technology, has announced the acquisition of Biolife Delaware, L.L.C., a company based in Sarasota, Florida, known for its patented hemostatic devices under the brand names StatSeal and WoundSeal. The transaction, valued at approximately $120 million, sees Biolife becoming a wholly-owned subsidiary of Merit. This strategic acquisition is expected to enhance Merit's product portfolio by providing clinicians with advanced hemostasis solutions to improve post-procedure care. The acquisition is projected to add around $18 million in annual revenue by fiscal year 2026, with a strong growth trajectory. The financial guidance for the full year 2025 has been updated to reflect the impact of this acquisition.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000035), on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}